FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100694593> ?p ?o ?g. }

• W2100694593 endingPage "1359" @default.
• W2100694593 startingPage "1347" @default.
• W2100694593 abstract "To review the literature regarding the use of antiarrhythmic agents in the management of atrial flutter (AF), atrial fibrillation (Afib), junctional ectopic tachycardia (JET), and atrial ectopic tachycardia (AET) in infants and children. To discuss the advantages and disadvantages of specific agents in each type of arrhythmia in an effort to develop treatment guidelines.A MEDLINE search encompassing the years 1966-1996 was used to identify pertinent literature for discussion. Additional references were found in the articles, which were retrieved via MEDLINE.Clinical trials that address the use of antiarrhythmic agents for the treatment of supraventricular tachycardia, AF, Afib, JET, and AET in children were selected. Literature pertaining to dosage, pharmacokinetics, efficacy, and toxicity of antiarrhythmic agents in children were considered for possible inclusion in the review; information judged to be pertinent by the authors was included in the discussion.Although there are numerous reports of antiarrhythmic use in children, there are very few large studies designed that evaluate the use of specific antiarrhythmic agents in the treatment of AF, Afib, JET, or AET. Ideally, controlled clinical trials are used to develop clinical guidelines; however, in this situation, most data and information must be obtained from case series of children treated. Although the results from these types of studies may be useful in developing guidelines for the optimal use of these agents for the treatment of AF, Afib, JET, and AET, controlled trials are required for establishing standard treatment guidelines for all patients.Despite limited scientific evaluation of conventional agents in the treatment of AF, Afib, JET, or AET in children, they continue to be the standards of care. Most information regarding the use of conventional agents in children has been extrapolated from the adult literature. Little justification for the use of the agents or dosing in children is available. Controlled trials regarding the use of newer antiarrhythmic agents (propafenone, amiodarone, flecainide) are available; however, the variance in dosing schemes, presence of structural heart disease, and patient age may confound the results.Because of greater clinical experience, conventional antiarrhythmic agents generally remain as first-line therapy in the management of most supraventricular tachycardias in children. Atrial pacing or cardioversion to reestablish sinus rhythm is indicated for initial episodes of AF in infants, followed by chronic prophylactic therapy in those with significant structural heart disease or in infants in whom AF recurs. Attempts to eliminate AF in children outside the neonatal or infancy period should begin with trials of traditional agents such as digoxin or procainamide, and if unsuccessful, subsequent trials of amiodarone. Digoxin and beta-blockers remain the mainstay of therapy for children with Afib, followed by procainamide for treatment failures. Intravenous amiodarone, the newest addition to our antiarrhythmic armamentarium, is the most promising agent in the treatment of postoperative JET. This arrhythmia has been traditionally managed with corporal cooling and/or digoxin therapy; however, intravenous amiodarone may now be a valuable option. Although relatively unsuccessful in the management of congenital JET and AET, conventional agents are typically used prior to the initiation of long-term therapy with potentially more toxic agents such as amiodarone or propafenone. Additional well-designed, controlled trials are needed to further evaluate the comparative efficacy of agents such as flecainide, sotalol, moricizine, propafenone, and amiodarone in the management of AF, Afib, JET, and AET in children, as well as to evaluate the dosing and toxicity in various age groups." @default.
• W2100694593 created "2016-06-24" @default.
• W2100694593 creator A5025506799 @default.
• W2100694593 creator A5078131405 @default.
• W2100694593 creator A5084500772 @default.
• W2100694593 date "1997-11-01" @default.
• W2100694593 modified "2023-09-25" @default.
• W2100694593 title "Pharmacologic Management of Supraventricular Tachycardias in Children. Part 2: Atrial Flutter, Atrial Fibrillation, and Junctional and Atrial Ectopic Tachycardia" @default.
• W2100694593 cites W1487108754 @default.
• W2100694593 cites W1512926192 @default.
• W2100694593 cites W1568027745 @default.
• W2100694593 cites W1583354996 @default.
• W2100694593 cites W1604734099 @default.
• W2100694593 cites W1877516859 @default.
• W2100694593 cites W1963919706 @default.
• W2100694593 cites W1964999540 @default.
• W2100694593 cites W1967241462 @default.
• W2100694593 cites W1968694849 @default.
• W2100694593 cites W1969741418 @default.
• W2100694593 cites W1969919055 @default.
• W2100694593 cites W1970062687 @default.
• W2100694593 cites W1972716370 @default.
• W2100694593 cites W1973935619 @default.
• W2100694593 cites W1974070656 @default.
• W2100694593 cites W1974102857 @default.
• W2100694593 cites W1977474961 @default.
• W2100694593 cites W1978982277 @default.
• W2100694593 cites W1981199592 @default.
• W2100694593 cites W1982674474 @default.
• W2100694593 cites W1983920329 @default.
• W2100694593 cites W1984257671 @default.
• W2100694593 cites W1985918155 @default.
• W2100694593 cites W1986731384 @default.
• W2100694593 cites W1986802154 @default.
• W2100694593 cites W1988562442 @default.
• W2100694593 cites W1990623554 @default.
• W2100694593 cites W1992752539 @default.
• W2100694593 cites W1995929640 @default.
• W2100694593 cites W1996670408 @default.
• W2100694593 cites W1996833236 @default.
• W2100694593 cites W2003321268 @default.
• W2100694593 cites W2003986304 @default.
• W2100694593 cites W2004838741 @default.
• W2100694593 cites W2006562971 @default.
• W2100694593 cites W2008786742 @default.
• W2100694593 cites W2008796765 @default.
• W2100694593 cites W2013143041 @default.
• W2100694593 cites W2014138773 @default.
• W2100694593 cites W2016482152 @default.
• W2100694593 cites W2019998852 @default.
• W2100694593 cites W2021283980 @default.
• W2100694593 cites W2023491087 @default.
• W2100694593 cites W2027955212 @default.
• W2100694593 cites W2029739265 @default.
• W2100694593 cites W2031066763 @default.
• W2100694593 cites W2036441482 @default.
• W2100694593 cites W2036565046 @default.
• W2100694593 cites W2039477410 @default.
• W2100694593 cites W2043833409 @default.
• W2100694593 cites W2045327980 @default.
• W2100694593 cites W2045682371 @default.
• W2100694593 cites W2046028583 @default.
• W2100694593 cites W2048421171 @default.
• W2100694593 cites W2051835558 @default.
• W2100694593 cites W2055601480 @default.
• W2100694593 cites W2058556705 @default.
• W2100694593 cites W2058743848 @default.
• W2100694593 cites W2058939413 @default.
• W2100694593 cites W2059585527 @default.
• W2100694593 cites W2062522218 @default.
• W2100694593 cites W2063279692 @default.
• W2100694593 cites W2064907300 @default.
• W2100694593 cites W2066819291 @default.
• W2100694593 cites W2070698938 @default.
• W2100694593 cites W2070872236 @default.
• W2100694593 cites W2072840939 @default.
• W2100694593 cites W2073396391 @default.
• W2100694593 cites W2074424301 @default.
• W2100694593 cites W2074462354 @default.
• W2100694593 cites W2078607240 @default.
• W2100694593 cites W2082830426 @default.
• W2100694593 cites W2084942160 @default.
• W2100694593 cites W2085622702 @default.
• W2100694593 cites W2086938315 @default.
• W2100694593 cites W2086939523 @default.
• W2100694593 cites W2088520838 @default.
• W2100694593 cites W2089064329 @default.
• W2100694593 cites W2092502994 @default.
• W2100694593 cites W2095100357 @default.
• W2100694593 cites W2096552314 @default.
• W2100694593 cites W2102383964 @default.
• W2100694593 cites W2114069908 @default.
• W2100694593 cites W2132061985 @default.
• W2100694593 cites W2133769785 @default.
• W2100694593 cites W2135674289 @default.
• W2100694593 cites W2138573862 @default.
• W2100694593 cites W2145077887 @default.
• W2100694593 cites W2159321277 @default.

• next